CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The I3LUNG project aims to enhance immunotherapy outcomes for patients with advanced Non-Small Cell Lung Cancer by developing artificial intelligence tools that analyze complex data from multiple sources. This initiative seeks to improve survival rates, quality of life, and reduce healthcare costs through personalized…
Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% of treated patients benefit from IO in the long term.
Programmed Death-Ligand 1 (PD-L1) remains the only biomarker used to predict patient outcome to IO, though its efficacy is limited.
Other potential biomarkers have been identified, yet not validated in prospective randomized clinical trials, providing only partial evidence.
Due to the dynamic complexity of…
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Italy, Milano
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
